Skip to main content
    I

    Insulet Corporation (PODD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $145.29
    -7.19 (-4.72%)

    Market Cap: $10.58B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insulet Corporation (PODD) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Insulet (PODD) is expected to report earnings on Feb 16, 2027. In the quarter ended Sep 30, 2026, Insulet reported EPS of $1.99, above the $1.59 estimate. It beat the EPS estimate in each of the last 9 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    68%(26/38)
    Avg Surprise
    +35.86%
    Streak
    9 Q

    Upcoming Estimates

    Reports Feb 16, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.81
    Range$1.57 - $2.08
    27 analysts
    Revenue Consensus
    $919.43M
    Range$858.28M - $985.95M
    26 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.66
    Range$1.40 - $1.78
    17 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$1.63+1.8%
    60d ago$1.62+2.1%
    30d ago$1.64+1.1%
    7d ago$1.63+1.8%
    Current$1.66
    Revenue Consensus
    $851.33M
    Range$827.00M - $878.50M
    17 analysts

    Next Report

    PODD has an expected report date of Feb 16, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 16.8% above the $1.55 reported for the quarter ended Dec 31, 2025.

    PODD Earnings Call

    The latest PODD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, PODD beat 26, missed 10 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $842.00M, up 19.2% from $706.30M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.99$1.59$1.50 - $1.66+25.16%Beat+60.5%231 up, 2 downNov 4, 2026$842.00M
    Jun 30, 2026$1.66$1.44$1.36 - $1.55+15.28%Beat+41.9%220 up, 1 downAug 5, 2026$801.70M
    Mar 31, 2026$1.42$1.19$1.06 - $1.29+19.33%Beat+39.2%210 up, 2 downMay 6, 2026$761.70M
    Dec 31, 2025$1.55$1.48$1.32 - $1.86+4.73%Beat+34.8%200 up, 1 downFeb 18, 2026$783.70M
    Sep 30, 2025$1.24$1.15$1.01 - $1.28+7.83%Beat+37.8%201 up, 1 downNov 6, 2025$706.30M
    Jun 30, 2025$1.17$0.93$0.78 - $1.13+25.81%Beat+112.7%200 up, 1 downAug 7, 2025$649.10M
    Mar 31, 2025$1.02$0.79$0.63 - $1.16+29.11%Beat+39.7%182 up, 0 downMay 8, 2025$569.00M
    Dec 31, 2024$1.15$1.02$0.93 - $1.17+12.63%Beat-17.9%157 up, 4 downFeb 20, 2025$597.50M
    Sep 30, 2024$0.90$0.76$0.70 - $0.86+18.42%Beat+26.8%170 up, 0 downNov 7, 2024$543.90M
    Jun 30, 2024$0.55$0.56$0.46 - $0.73-1.79%Miss+44.7%191 up, 0 downAug 8, 2024$488.50M
    Mar 31, 2024$0.73$0.39$0.28 - $0.61+87.18%Beat+217.4%161 up, 0 downMay 9, 2024$441.70M
    Dec 31, 2023$1.40$0.66$0.50 - $0.82+112.12%Beat+483.3%160 up, 0 downFeb 22, 2024$509.80M
    Sep 30, 2023$0.71$0.41$0.26 - $0.55+73.17%Beat+73.2%181 up, 0 downNov 2, 2023$432.70M
    Jun 30, 2023$0.38$0.26$0.13 - $0.36+46.15%BeatN/A180 up, 0 downAug 8, 2023$396.50M
    Mar 31, 2023$0.23$0.10$0.03 - $0.25+130.00%Beat-42.5%150 up, 0 downMay 4, 2023$358.10M
    Dec 31, 2022$0.24$0.21$0.04 - $0.42+14.29%Beat-42.9%170 up, 0 downFeb 23, 2023$369.70M
    Sep 30, 2022$0.41$0.14$0.07 - $0.21+192.86%Beat+105.0%150 up, 2 downNov 3, 2022$340.80M
    Jun 30, 2022-$0.08$0.23N/A-134.78%Miss-153.3%N/A0 up, 1 downAug 4, 2022$299.40M
    Mar 31, 2022$0.40$0.24$0.11 - $0.29+66.67%BeatN/A150 up, 1 downMay 5, 2022$295.40M
    Dec 31, 2021$0.42$0.32$0.22 - $0.44+31.25%BeatN/A170 up, 0 downFeb 23, 2022$307.70M
    Sep 30, 2021$0.20$0.25$0.11 - $0.39-20.00%Miss+17.6%21N/ANov 4, 2021$275.60M
    Jun 30, 2021$0.15$0.14$0.05 - $0.24+7.14%Beat-31.8%21N/AAug 5, 2021$263.20M
    Mar 31, 2021Not reported$0.09-$0.08 - $0.22N/ANot reportedN/A19N/AMay 6, 2021$252.30M
    Dec 31, 2020-$0.04-$0.04-$0.19 - $0.150.00%In line-140.0%18N/AFeb 23, 2021$246.10M
    Sep 30, 2020$0.17$0.08-$0.04 - $0.25+112.50%Beat+88.9%20N/ANov 4, 2020$234.00M
    Jun 30, 2020$0.22$0.01-$0.08 - $0.16N/AN/A+1000.0%20N/AAug 6, 2020$226.30M
    Mar 31, 2020-$0.03-$0.01-$0.10 - $0.11-200.00%Miss-142.9%19N/AMay 7, 2020$198.00M
    Dec 31, 2019$0.10$0.12-$0.02 - $0.27-16.67%Miss-37.5%17N/AFeb 25, 2020$209.40M
    Sep 30, 2019$0.09$0.04-$0.11 - $0.11+125.00%Beat+200.0%16N/ANov 5, 2019$192.10M
    Jun 30, 2019$0.02$0.03-$0.14 - $0.10-33.33%MissN/A18N/AAug 5, 2019$177.10M
    Mar 31, 2019$0.07$0.01-$0.04 - $0.15+600.00%BeatN/A18N/AMay 2, 2019$159.60M
    Dec 31, 2018$0.16$0.07$0.02 - $0.16+128.57%BeatN/A18N/AFeb 25, 2019$164.88M
    Sep 30, 2018$0.03$0.03-$0.23 - $0.060.00%In lineN/A17N/ANov 1, 2018$151.08M
    Jun 30, 2018-$0.03-$0.13-$0.23 - -$0.07+76.92%BeatN/A17N/AAug 2, 2018$124.26M
    Mar 31, 2018-$0.11-$0.18-$0.28 - -$0.08+38.89%BeatN/A17N/AMay 3, 2018$123.58M
    Dec 31, 2017-$0.12-$0.08-$0.15 - -$0.01-50.00%MissN/A16N/AFeb 21, 2018$130.56M
    Sep 30, 2017-$0.04-$0.10-$0.16 - -$0.03+60.00%BeatN/A17N/ANov 2, 2017$121.78M
    Jun 30, 2017-$0.13-$0.12-$0.17 - -$0.04-8.33%MissN/A16N/AAug 3, 2017$109.76M
    Mar 31, 2017-$0.17-$0.15N/A-13.33%MissN/AN/AN/AMay 8, 2017$101.71M
    Dec 31, 2016-$0.16-$0.05N/A-220.00%MissN/AN/AN/AFeb 27, 2017$103.58M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $4.98, up 49.5% from the year before. It was -$0.44 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$4.98+49.5%
    Dec 31, 2024$3.33+22.4%
    Dec 31, 2023$2.72+180.4%
    Dec 31, 2022$0.97+26.0%
    Dec 31, 2021$0.77+140.6%
    Dec 31, 2020$0.32N/A
    Dec 31, 2019$0.28+460.0%
    Dec 31, 2018$0.05N/A
    Dec 31, 2017-$0.46N/A
    Dec 31, 2016-$0.44N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,600 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,64813
    2026Q2Jun 30, 20266,70214
    2026Q1Mar 31, 20266,73414
    2025Q4Dec 31, 20258,57514
    2025Q3Sep 30, 20257,50018
    2025Q2Jun 30, 20258,09320
    2025Q1Mar 31, 20256,61318
    2024Q4Dec 31, 20249,20519

    2026Q3 Earnings Call

    Opening remarks

    Clare Trachtman Vice President, Investor Relations Good morning, and welcome to our third quarter 2026 earnings call. Joining me today are Ashley A. McEvoy, President and Chief Executive Officer, and Flavia H. Pease, Chief Financial Officer. On the call this morning, we will be discussing Insulet's third quarter results along with our financial outlook for the fourth quarter and full year 2026. With that, let me start our prepared remarks by reminding everyone that certain statements, including comments regarding our financial outlook, the anticipated impact of our strategic actions, the potential impact of various regulatory and operational matters, and the macroeconomic environment on our results of operations, contain forward-looking statements that involve risks and uncertainties. And, of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially. In addition, on today's call, non-GAAP financial measures will be used to help investors understand Insulet's ongoing business performance, including adjusted operating income, adjusted EPS, adjusted tax rate, and constant-currency revenue, which is revenue growth excluding the effect of foreign exchange. A reconciliation of certain non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in the accompanying investor presentation and available in our earnings release issued this morning, both of which are available on our website. Additionally, unless otherwise stated, all financial commentary regarding dollar and percentage changes will be on a year-over-year reported basis, with the exception of revenue growth rates, which will be on a year-over-year constant-currency basis. During the Q&A session this morning, Ashley, Flavia, and I will be available to address any questions. Now I would like to turn the call over to Ashley. Ashley?

    Ashley A. McEvoy President and CEO Good morning, everyone, and thanks for joining us to discuss our third quarter results. Our teams delivered a strong quarter, with U.S. performance in our guidance range and international performance that exceeded our plans. As we near the end of the year, we have narrowed our total company full-year outlook to the top end of our prior range to reflect this strength. Throughout the quarter, we continued advancing our strategic priorities: strengthening our commercial capabilities and execution, accelerating innovation, and expanding the category by increasing access and building relationships with prescribers. Importantly, we made progress against the type 2 action plan we laid out on our quarter 2 call. We are pleased with our progress in the quarter, and I want to take a step back and provide some broader perspective. Insulet has a strong leadership position in one of the largest, fastest-growing, and most underpenetrated segments in med tech.

    Frequently Asked Questions About PODD

    When is Insulet's next earnings date?

    Insulet's next earnings report is expected for Feb 16, 2027.

    Did PODD beat earnings estimates last quarter?

    Yes. Insulet reported EPS of $1.99 for the quarter ended Sep 30, 2026, above the $1.59 estimate, a 25.16% surprise.

    What EPS do analysts expect from PODD next quarter?

    The consensus EPS estimate for Insulet for the quarter ending Dec 31, 2026 is $1.81 from 27 analysts, with estimates from $1.57 to $2.08.

    How often does PODD beat earnings estimates?

    Insulet beat the EPS estimate in each of the last 9 quarters, with an average surprise of +17.59%.